LIFECORE BIOMEDICAL, INC. Restructuring Costs
LIFECORE BIOMEDICAL, INC. (LFCR) reported Restructuring Costs of $4.18 million for the 12-month period ending 2023-05-28, per its 10-K filed 2024-03-20.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2024-03-20
- LIFECORE BIOMEDICAL, INC. restructuring costs for the quarter ending 2023-05-28 was $8.00K, a 99.03% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. restructuring costs for the quarter ending 2023-02-26 was $2.57M, a 51.35% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. restructuring costs for the quarter ending 2022-11-27 was $563.00K, a 10.21% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. restructuring costs for the quarter ending 2022-08-28 was $1.05M, a 7.18% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. restructuring costs for fiscal 2023 was $4.18M, a 49.95% decline from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. restructuring costs for fiscal 2022 was $8.36M, a 37.41% decline from fiscal 2021.
- LIFECORE BIOMEDICAL, INC. restructuring costs for fiscal 2021 was $13.36M, a 22.74% decline from fiscal 2020.
- LIFECORE BIOMEDICAL, INC. restructuring costs for fiscal 2020 was $17.29M.
| Period end | Restructuring Costs 3 month | Restructuring Costs 3 month as first filed | Restructuring Costs 6 month | Restructuring Costs 6 month as first filed | Restructuring Costs 9 month | Restructuring Costs 9 month as first filed | Restructuring Costs 12 month | Restructuring Costs 12 month as first filed | Restructuring Costs 15 month | Restructuring Costs 18 month | Restructuring Costs 21 month | Restructuring Costs 24 month | Restructuring Costs 27 month | Restructuring Costs 30 month | Restructuring Costs 33 month | Restructuring Costs 36 month | Restructuring Costs 36 month as first filed | Restructuring Costs 39 month | Restructuring Costs 42 month | Restructuring Costs 45 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-28 | $8.00K derived: 10-K 12 month − 10-K 9 month · filed 2024-03-20 | $2.57M derived: sum of 2 quarters · filed 2024-03-20 | $3.14M derived: sum of 3 quarters · filed 2024-03-20 | $4.18M 10-K · filed 2024-03-20 | ||||||||||||||||
| 2023-02-26 | $2.57M 10-K · filed 2024-03-20 | $2.74M 10-Q · filed 2023-06-02 | $3.13M derived: sum of 2 quarters · filed 2024-03-20 | $4.18M 10-K · filed 2024-03-20 | $4.61M 10-Q · filed 2023-06-02 | $5.00M derived: sum of 4 quarters · filed 2024-03-20 | $21.39M 10-Q · filed 2023-06-02 | |||||||||||||
| 2022-11-27 | $563.00K 10-K · filed 2024-03-20 | $823.00K 10-Q · filed 2023-03-16 | $1.61M 10-K · filed 2024-03-20 | $1.87M 10-Q · filed 2023-03-16 | $2.44M derived: sum of 3 quarters · filed 2024-03-20 | $7.71M derived: sum of 4 quarters · filed 2024-03-20 | $18.65M 10-Q · filed 2023-03-16 | |||||||||||||
| 2022-08-28 | $1.05M 10-Q/A · filed 2023-03-16 | $1.88M derived: sum of 2 quarters · filed 2024-03-20 | $7.15M derived: sum of 3 quarters · filed 2024-03-20 | $7.78M derived: sum of 4 quarters · filed 2024-03-20 | $17.82M 10-Q/A · filed 2023-03-16 | |||||||||||||||
| 2022-05-29 | $829.00K derived: 10-K 12 month − 10-K/A 9 month · filed 2024-03-20 | $6.10M derived: sum of 2 quarters · filed 2024-03-20 | $6.73M derived: sum of 3 quarters · filed 2024-03-20 | $8.36M 10-K · filed 2024-03-20 | $8.96M 10-K · filed 2022-09-14 | $29.96M 10-K · filed 2024-03-20 | $16.78M 10-K · filed 2022-09-14 | |||||||||||||
| 2022-02-27 | $5.27M 10-K · filed 2024-03-20 | $5.87M 10-Q · filed 2022-04-07 | $5.90M derived: sum of 2 quarters · filed 2024-03-20 | $7.53M 10-K/A · filed 2023-03-16 | $8.41M 10-Q · filed 2022-04-07 | $7.62M derived: sum of 4 quarters · filed 2024-03-20 | $16.22M 10-Q · filed 2022-04-07 | |||||||||||||
| 2021-11-28 | $627.00K 10-K · filed 2024-03-20 | $1.41M 10-Q · filed 2022-01-07 | $1.75M 10-K · filed 2024-03-20 | $3.97M 10-Q · filed 2022-01-07 | $2.34M derived: sum of 3 quarters · filed 2024-03-20 | $4.42M derived: sum of 4 quarters · filed 2024-03-20 | $41.44M 10-Q · filed 2022-01-07 | |||||||||||||
| 2021-08-29 | $1.13M 10-K · filed 2024-03-20 | $2.56M 10-Q · filed 2021-10-05 | $1.72M derived: sum of 2 quarters · filed 2024-03-20 | $3.79M derived: sum of 3 quarters · filed 2024-03-20 | $37.47M 10-Q · filed 2021-10-05 | |||||||||||||||
| 2021-05-30 | $589.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $2.66M derived: sum of 2 quarters · filed 2024-03-20 | $13.36M 10-K · filed 2024-03-20 | $17.62M 10-K · filed 2021-07-29 | $34.91M 10-K · filed 2021-07-29 | |||||||||||||||
| 2021-02-28 | $2.07M 10-K · filed 2024-03-20 | $2.70M 10-Q · filed 2021-04-08 | $12.77M 10-Q · filed 2021-04-08 | |||||||||||||||||
| 2021-02-23 | $2.70M derived: 10-Q 21 month − 10-Q 18 month · filed 2021-04-08 | $3.80M derived: sum of 2 quarters · filed 2024-03-20 | $10.47M derived: sum of 3 quarters · filed 2024-03-20 | $13.82M derived: sum of 4 quarters · filed 2024-03-20 | $30.05M 10-Q · filed 2021-04-08 | |||||||||||||||
| 2020-11-29 | $1.10M 10-K · filed 2024-03-20 | $1.66M 10-Q · filed 2021-01-07 | $7.77M 10-K · filed 2024-03-20 | $10.07M 10-Q · filed 2021-01-07 | $11.12M derived: sum of 3 quarters · filed 2024-03-20 | $24.64M derived: sum of 4 quarters · filed 2024-03-20 | $27.35M 10-Q · filed 2021-01-07 | |||||||||||||
| 2020-08-30 | $6.67M 10-K · filed 2024-03-20 | $8.40M 10-Q · filed 2020-10-07 | $10.02M derived: sum of 2 quarters · filed 2024-03-20 | $23.55M derived: sum of 3 quarters · filed 2024-03-20 | $23.55M derived: sum of 4 quarters · filed 2024-03-20 | $25.69M 10-Q · filed 2020-10-07 | ||||||||||||||
| 2020-05-31 | $3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2020-08-14 | $16.88M derived: sum of 2 quarters · filed 2021-04-08 | $16.88M derived: sum of 3 quarters · filed 2021-04-08 | $17.29M 10-K · filed 2020-08-14 | ||||||||||||||||
| 2020-02-23 | $13.53M 10-Q · filed 2021-04-08 | $13.53M derived: sum of 2 quarters · filed 2021-04-08 | $13.93M 10-Q · filed 2021-04-08 | |||||||||||||||||
| 2019-11-24 | $0.00 10-Q · filed 2021-01-07 | $0.00 10-Q · filed 2021-01-07 | ||||||||||||||||||
| 2019-08-25 | $0.00 10-Q · filed 2020-10-07 | |||||||||||||||||||
| 2019-02-24 | $0.00 10-Q · filed 2020-04-03 | $0.00 10-Q · filed 2020-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |